Nevertheless, PDX-cell enrichment rates would still be sufficient for diagnostic tumor cell analysis with acceptable loss of CD34+ cells, especially when considering that only a small fraction of the PBPC product needs to be processed for tumor cell diagnostics. The gene discussed is CD34; the disease is neoplasm.